| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to levodop prodrugs, their stereoisomers, enantiomers or pharmaceutically acceptable salts and based on them pharmaceutical composition for ensuring slowed levodop release, as well as to versions of their application and methods of obtaining them, compounds can be applied for treatment or prevention of diseases in which levodop application is indicated. In general formula (I): , Q is selected from X-CO-; X is selected from -O- and -NH-; n equals integer number from 2 to 4; each R 1 and R 2 is independently selected from hydrogen, -OH, C 1-4 alkyl and substituted C 1-4 alkyl, where substituting group is -OH; R 3 and R 4 represent hydrogen; R 5 is selected from hydrogen, C 1-4 alkyl, phenyl, substituted phenyl, where each substituting group is independently selected from C 1-6 alcoxy, C 1-6 alkyl, halogen and -OH; C 3-8 cycloalkyl, pyridyl, substituted pyridyl, where each substituting group is independently selected from C 1-6 alkyl and C 1-6 alcoxy; on condition that formula (I) compound is not a derivative of 1,3-dihexadecanoylpropane-1,2,3-triol. n EFFECT: elaboration of pharmaceutical composition for ensuring slowed levodop release. n 48 cl, 4 dwg, 32 ex |